HitGen (SHSE:688222) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688222 HitGen Inc SHSE:688222
90 GF Score
Price ¥29.16
GF Value ¥26.07
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is HitGen Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

SHSE:688222 vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, HitGen's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HitGen Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HitGen's Short Interest distribution charts can be found below:

* The bar in red indicates where HitGen's Short Interest falls into.


SHSE:688222
90GF Score
HitGen Inc SHSE:688222
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HitGen (SHSE:688222) Overvalued in 2026?

Based on GuruFocus' analysis, HitGen stock appears to be overvalued. The current stock price of ¥29.16 is trading 11.9% above its estimated GF Value™ of ¥26.07. GuruFocus considers HitGen to be Modestly Overvalued.

Key valuation signals for SHSE:688222:

  • Short Interest:
  • GF Value™: ¥26.07 vs. price of ¥29.16 (11.9% above fair value)
  • GF Score™: 90/100 with 1 warning sign

No single metric tells the full story. See the SHSE:688222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HitGen Business Description

Address Section 2, Biocity Middle Road, Chengdu Tianfu International Biological City, No. 18, Shuangliu District, Sichuan Province, Chengdu, CHN, 610093
HitGen Inc is dedicated to building a world-class biopharmaceutical enterprise. Its mission is to advance human health and quality of life. It provides therapeutic solutions to address unmet medical needs. Centered on its internationally DEL (DNA-encoded Library) technology, the Company has expanded into Fragment-Based Drug Discovery and Structure-Based Drug Design and a suite of complementary platforms based on Oligonucleotide-based Therapeutics, Targeted Proximity Drugs, and Cyclic Peptidomimetics. The group has developed HAILO, a proprietary "DEL+AI+Automation" molecular optimization platform, thereby establishing a distinctive novel molecule discovery engine that delivers both therapeutic molecules and tool molecules to the world-wide pharmaceutical industry.
90GF Score

Get the complete analysis for SHSE:688222

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥29.16
Price
¥26.07
GF Value